期刊文献+

腹膜透析相关性腹膜炎生物学标志物研究进展 被引量:7

暂未订购
导出
摘要 腹膜透析(peritoneal dialysis,PD)作为终末期肾脏疾病(end-stage renal disease,ESRD)患者肾脏替代治疗的主要方式之一,相较于血液透析(hemo dialysis,HD)而言,因其在改善患者的生存质量、保护残余肾功能、中分子物质清除效果好、血流动力学稳定等方面的优势而被患者所接受。但是,腹膜透析管长期留置腹腔、反复换液及部分患者操作欠规范等易导致感染性腹膜炎。
出处 《中国血液净化》 2012年第11期630-632,共3页 Chinese Journal of Blood Purification
基金 国家自然科学基金"microRNA302c在腹膜透析腹膜纤维化中的作用及分子机制"(81070610)
  • 相关文献

参考文献15

  • 1Li,P.K,C.C.Szeto,B.Piraino. Peritoneal dialysis-related infections recommendations:2010 update[J].Peritoneal Dialysis International,2010.393-423.
  • 2Lam,M.F,J.C.Leung,C.W.Lam. Procalcitonin fails to differentiate inflammatory status or predict long-term outcomes in peritoneal dialysis-associated peritonitis[J].Peritoneal Dialysis International,2008.377-384.
  • 3Ducloux,D,C.Bresson-Vautrin,M.Kribs. Creactive protein and cardiovascular disease in peritoneal dialysis patients[J].Kidney International,2002.1417-1422.
  • 4Riquelme,A,M.Calvo,F.Salech. Value of ad enosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis:a meta-analysis[J].Journal of Clinical Gastroenterology,2006.705-710.
  • 5苗里宁,顾华,李红.腹膜透析患者透析液中腺苷脱氨酶活性测定及其临床意义[J].吉林医学,2000,21(4):199-200. 被引量:5
  • 6Pecoits-Filho,R,P.Barany,B.Lindholm. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment[J].Nephrology Dialysis Transplantation,2002.1684-1688.
  • 7Zemel,D,R.T.Krediet,G.C.Koomen. Interleukin-8 during peritonitis in patients treated with CAPD; an in-vivo model of acute inflammation[J].Nephrology Dialysis Transplantation,1994.169-174.
  • 8张爱华,范敏华,郑丹侠,杨雪玲.腹膜透析患者CA125水平及腹膜转运功能的纵向观察[J].中国血液净化,2002,1(8):7-9. 被引量:1
  • 9Krediet,R.T. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis[J].Peritoneal Dialysis International,2001.560-567.
  • 10Hirahara,I,M.Inoue,K.Okuda. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury,increased solute transport,or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan[J].Nephrology Dialysis Transplantation,2007.560-567.

二级参考文献9

  • 1苗里宁,顾华,董云珠,罗萍,陈云波.慢性肾功能竭衰病人的腺苷脱氨酶活性研究[J].中华肾脏病杂志,1994,10(4):226-227. 被引量:2
  • 2中华肾脏病学会上海分会透析学组讨论纪要.关于腹膜透析腹膜炎的几个问题[J].中华肾脏病杂志,1987,3(4):170-170.
  • 3[1]Visser CE, Brouwer-Steenbergen JJE,Betjes MGH,et al.Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients Nephrol Dial Transplant, 1995,10(1):64-69
  • 4[2]Pannekeet MM,Hiralall JK, Struijk DG et al.Longitudinal follow-up of CA125 in peritoneal effluent.Kidney Int,1997,51:888-893
  • 5[3]Pannekeet MM,Zemel D,Koomen GCM, et al.Dialysate markers of peritoneal tissue during peritonitis and stable CAPD. Perit dial Int,1995,15:217-225
  • 6[4]Davies SJ,Phillips L,Griffiths AM, et al.What really Happens to people on long-term peritoneal dialysis? Kidney Int,1998,54:2208-2217
  • 7[5]Davies SJ, Bryan J, Phillips L, et al.Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephol Dial Transplant,1996,11:498-496
  • 8[6]Lai FM, Lai KB,Szeto CC, et al.Dialysate cell population and cancer antigen 125 in stable continuious ambulatory peritoneal dialysis patients:their relationship with transport parameters.Am J Kidney Dis,1997,29(4):699-705
  • 9苗里宁,董云珠,顾华,李红,王淑芹,于彩莲.腹膜透析透出液腺苷脱氨酶活性测定及其临床意义[J].中国实验诊断学,1997,1(5):37-38. 被引量:1

共引文献4

同被引文献52

引证文献7

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部